Want to see JP:4118 full AI Analyst Report?
4118 Stock Chart & Stats
¥5841.00
¥45.00(0.77%)
At close: 4:00 PM EDT
¥5841.00
¥45.00(0.77%)
Day’s Range― - ―
52-Week Range¥4,082.00 - ¥6,099.00
Previous CloseN/A
Volume208.60K
Average Volume (3M)189.42K
Market Cap
¥364.33B
Enterprise Value¥497.58K
Total Cash (Recent Filing)¥50.97B
Total Debt (Recent Filing)¥231.31B
Price to Earnings (P/E)12.2
Beta0.83
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.62%
Share Statistics
EPS (TTM)502.44
Shares Outstanding63,000,000
10 Day Avg. Volume277,740
30 Day Avg. Volume189,416
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)0.59
Price to Sales (P/S)0.37
P/FCF Ratio219.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥5,733.33Price Target Upside-1.84% Downside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)486.32
Revenue Forecast (FY)¥870.47B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthConsistent multi-year revenue growth indicates durable end-market demand and pricing power across product lines. Sustained top-line expansion supports reinvestment in capacity, application development and specialty product R&D, improving competitive positioning over the medium term.
Diversified End-Market ExposureA broad portfolio across industrial materials and healthcare/nutrition reduces reliance on any single end market. This diversification cushions cyclicality, enables cross-selling, and increases exposure to higher-margin specialty and healthcare segments that compound returns over time.
Reasonable Balance SheetSteady equity growth and moderate leverage provide capacity to fund capital expenditures and strategic investments without extreme refinancing pressure. A healthier equity base supports long-term operational stability and the ability to absorb shocks or pursue selective M&A.
Bears Say
Volatile Free Cash FlowFree cash flow volatility and multiple years of negative FCF imply accounting profits don't consistently convert to cash. That limits internal funding for dividends, buybacks or debt reduction, increases dependence on external financing, and raises execution risk over the medium term.
Modest Net MarginsLow net margins despite strong revenue growth indicate limited bottom-line leverage. Modest profitability reduces the firm's ability to absorb raw-material cost shocks, restrains retained earnings for reinvestment, and makes meaningful ROE improvement contingent on mix or cost gains.
Rising Leverage & Modest ROEAn upward trend in debt paired with mid-single-digit ROE raises concerns about capital efficiency. Increasing leverage with modest returns heightens financial rigidity and interest-rate sensitivity, limiting flexibility to pursue growth or shareholder-friendly capital allocation.
Kaneka News
4118 FAQ
What was Kaneka Corporation’s price range in the past 12 months?
Kaneka Corporation lowest stock price was ¥4082.00 and its highest was ¥6099.00 in the past 12 months.
What is Kaneka Corporation’s market cap?
Kaneka Corporation’s market cap is ¥364.33B.
When is Kaneka Corporation’s upcoming earnings report date?
Kaneka Corporation’s upcoming earnings report date is Nov 11, 2026 which is in 89 days.
How were Kaneka Corporation’s earnings last quarter?
Kaneka Corporation released its earnings results on Aug 13, 2026. The company reported ¥148.46 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Kaneka Corporation overvalued?
According to Wall Street analysts Kaneka Corporation’s price is currently Overvalued.
Does Kaneka Corporation pay dividends?
Kaneka Corporation pays a Semiannually dividend of ¥105 which represents an annual dividend yield of 2.62%. See more information on Kaneka Corporation dividends here
What is Kaneka Corporation’s EPS estimate?
Kaneka Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kaneka Corporation have?
Kaneka Corporation has 63,000,000 shares outstanding.
What happened to Kaneka Corporation’s price movement after its last earnings report?
Kaneka Corporation reported an EPS of ¥148.46 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.807%.
Which hedge fund is a major shareholder of Kaneka Corporation?
Currently, no hedge funds are holding shares in JP:4118
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kaneka Corporation
Kaneka Corporation, established in Tokyo, Japan, in 1949, operates internationally as a diversified manufacturer providing a wide array of advanced materials and specialized products. Its core chemical business includes the production and global distribution of various polyvinyl chloride (PVC) formulations, such as crosslinked, paste, and chlorinated PVC, alongside acryl grafted-vinyl chloride copolymers. The company also supplies critical additives like impact modifiers, processing aids, specialty additives, and tougheners for thermosetting resins. Furthermore, their portfolio features advanced polymers including silyl-terminated polyether, acrylic silicon, terminally reactive liquid acrylic, biodegradable polymers, and engineering resins designed for injection molding, in addition to zero birefringence materials, acrylic films, and isobutylene-based thermoplastic elastomers. Beyond chemicals, Kaneka manufactures specialized foams and films, encompassing polypropylene and Kanelite foams, extruded polystyrene insulation, polyimide films, and transparent films for optical applications. Their material science expertise extends to high thermal conductive graphite sheets, multi-layer insulation, transparent conductive films, and transparent resins engineered for exceptional heat and light resistance. In the energy and innovative products sector, Kaneka offers photovoltaic power generation systems suitable for residential, public, and industrial installations. Other cutting-edge developments include eco-friendly fur, flame-retardant materials, hair accessories, novel materials, organic EL lighting panels, and biosurfactants. Their life sciences division delivers a comprehensive range of medical and pharmaceutical offerings, which include intervention and blood purification systems, gastroenterology intervention tools, diagnostic testing equipment, regenerative medicine and cell therapy solutions, and genetic diagnostics. Additionally, they provide low molecular pharmaceutical raw materials, affinity chromatography resins for monoclonal antibody purification, biopharmaceuticals, transdermal medicines, and innovative shock-absorbing innerwear. Lastly, Kaneka is a significant player in the food and nutrition industry. Their extensive product line features dairy products, margarines, fats and oils, whipping creams, fillings, baking essentials (baker's yeast, dough improvers), processed fruits, butter, shortening, cacao butter alternatives, various creams, frozen dough, spices, and antifreeze materials. They also supply pharmaceutical and supplemental nutrition solutions, such as coenzyme Q10, lactic-acid bacteria, and functional foodstuffs, alongside agricultural fertilizers.
4118 Stock 12 Month Forecast
Average Price Target
¥5,733.33
▼(-1.84% Downside)






